<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727113</url>
  </required_header>
  <id_info>
    <org_study_id>Optimbioma</org_study_id>
    <nct_id>NCT03727113</nct_id>
  </id_info>
  <brief_title>Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors</brief_title>
  <acronym>Optimbioma</acronym>
  <official_title>Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors: Impact on Intestinal Microbiota and in Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grupo Espanol de trasplantes hematopoyeticos y terapia celular</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are data suggesting that the reduction of the diversity of intestinal microbiota caused
      by the used treatments in the setting of allogeneic hemopoietic stem cell transplant (ASCT),
      and specially antibiotics, may be related to increased incidence of graft versus host disease
      (GVHD) and worst clinical outcomes. Present &quot;European Conference on Infections in Leukaemia&quot;
      guidelines exhort to antibiotic treatment optimization in hematological patients, without
      excluding ASCT receptors. This study aims to demonstrate that in ASCT receptors a predefined
      protocol of optimization of the antibacterial treatment will preserve the intestinal
      microbiota diversity which will correlate with decrease incidence of acute GVHD. And that
      this procedure is safe because it will not worsen the incidence of infections, transplant
      related mortality, infectious mortality or global survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact on microbiota</measure>
    <time_frame>From the Previous Day of starting conditioning treatment until the last documented day of antibiotherapy or hospital discharge, whichever came first, assessed up to one month post-transplant.</time_frame>
    <description>Comparison of biological alpha and beta diversity of the intestinal microbiota of both study groups (classical and optimized antibiotherapy). Calculation of alpha diversity (OTUs richness and Shannon diversity indexes observed, Faith's Phylogenetic Diversity and Evenness) and beta diversity (Jaccard distance, Bray-Curtis distance, Unweighted UniFra distance, used for comparing biological communities) indexes by QIIME 2 (microbiome bioinformatics platform).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute graft versus host disease</measure>
    <time_frame>From the day of transplant (Day 0) to Day +100 posttransplant</time_frame>
    <description>Comparison of the incidence of any degree, degree-II and degree-III/IV of acute graft versus host disease between the groups of patients with high and low diversity in their microbiota. Cumulative Incidence curve estimation.
Test for the comparison of groups: Gray Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>From the day of transplant (Day 0) to Days +30, +100 and +365 posttransplant</time_frame>
    <description>Comparison of transplant related mortality between both study groups (classical and optimized antibiotherapy). Cumulative Incidence curve estimation. Test for the comparison of groups: Gray Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality caused by infection</measure>
    <time_frame>From the day of transplant (Day 0) to Days +30, +100 and +365 posttransplant</time_frame>
    <description>Comparison of infection related mortality between both study groups (classical and optimized antibiotherapy. Cumulative Incidence curve estimation. Test for the comparison of groups: Gray Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe infections</measure>
    <time_frame>From the day of transplant (Day 0) to Day +30 posttransplant</time_frame>
    <description>Comparison of the incidence of severe infections between both study groups (classical and optimized antibiotherapy). Cumulative Incidence curve estimation. Test for the comparison of groups: Gray Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the day of transplant (Day 0) to Days +30, +100 and +365 posttransplant</time_frame>
    <description>Comparison of overall survival between both study groups (classical and optimized antibiotherapy) Kaplan-Meier curve estimation. Test for the comparison of groups: Log-Rank Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From the day of transplant (Day 0) to Days +30, +100 and +365 posttransplant</time_frame>
    <description>Comparison of the diseae free survival between both study groups (classical and optimized antibiotherapy Kaplan-Meier curve estimation. Test for the comparison of groups: Log-Rank Test.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <description>Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimization cohort</arm_group_label>
    <description>Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optimization cohort</intervention_name>
    <description>Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.</description>
    <arm_group_label>Optimization cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control cohort</intervention_name>
    <description>Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.</description>
    <arm_group_label>Control cohort</arm_group_label>
  </intervention>
  <biospec_descr>
    <textblock>
      Stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (&gt; 18 years old) who are going to receive their first hematopoietic
        allogeneic transplant of any modality and who sign the informed consent to participate in
        this study will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to receive their first allogeneic hematopoietic transplant as a
             treatment of any disease.

          -  Conformity of the patient to participate by signing the informed consent.

          -  Patients who have received a previous autologous transplant are not excluded.

        Exclusion Criteria:

          -  Non-compliance of the patient to sign the informed consent.

          -  Patients who have already started the conditioning (or thereafter) will not be
             included.

          -  Allograft recipients who have previously received the transplant will not be included.
             Second allogeneic transplants are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ildefonso Espigado, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Service, Hematopoietic Transplant Program, Seville Biomedicine Institute (IBIS) - Virgen del Rocío University Hospital, Seville.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ildefonso Espigado, PhD, MD</last_name>
    <phone>0034 697966979</phone>
    <email>ildefonso.espigado.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara M Rosso-Fernández, PhD, MD</last_name>
    <phone>0034 955012144</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virgen del Rocío University Hospital, Seville.</name>
      <address>
        <city>Sevilla</city>
        <state>Seville</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ildefonso Espigado, PhD, MD</last_name>
      <phone>0034 697966979</phone>
      <email>ildefonso.espigado.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Rodríguez, PhD, MD</last_name>
      <phone>0034 955 01 2228</phone>
      <email>nanarotor@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gregorio Marañón University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Kwon, MD</last_name>
      <phone>0034 915868443</phone>
      <email>mi.kwon@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salamanca University Hospital</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María L Vazquez Lopez, MD</last_name>
      <email>lvazlo@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marqués de Valdecilla University Hospital</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucrecia Yáñez, MD</last_name>
      <phone>0034 942 202573</phone>
      <email>lucrecia@humv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital of Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Solano Vercet, MD</last_name>
      <email>carlos.solano@uv.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Cebrecos C, Falantes J, Vázquez-López L, Montero MI, Rosso-Fernández C, de la Luz Martino M, Parody R, González-Campos J, Garzón-López S, Calderón-Cabrera C, Barba P, Rodríguez N, Rovira M, Montero-Mateos E, Carratalá J, Pérez-Simón JA, Cisneros JM. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017 Dec;4(12):e573-e583. doi: 10.1016/S2352-3026(17)30211-9. Epub 2017 Nov 15.</citation>
    <PMID>29153975</PMID>
  </reference>
  <reference>
    <citation>Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013 Dec;98(12):1826-35. doi: 10.3324/haematol.2013.091025. Erratum in: Haematologica. 2014 Feb;99(2):400.</citation>
    <PMID>24323983</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiota</keyword>
  <keyword>microbiome</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>infection</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

